CHICAGO, Aug. 20, 2012 /PRNewswire/ — Positron Corporation (OTCBB: POSC) a leading molecular imaging healthcare company, is pleased to announce the FDA’s marketing approval of The University of Texas Health Science Center at Houston (UTHealth) Coronary Flow Reserve (CFR) quantification software, cfrQuant™.

The cfrQuant™ software was developed under the guidance of K. Lance Gould, M.D., and the Weatherhead PET Imaging Center of the UTHealth Medical School, with contributions of software segments from Positron Corporation.

Positron will distribute and support cfrQuant™ to its current and future U.S. based cardiac PET customers, under a licensing agreement with UTHealth. The cfrQuant™ software has been approved for use with 82Rb-chloride and 13N-ammonia. Dr. Gould has recused himself of receiving royalties in support of academic programs.

Joseph Oliverio, Chief Technology Officer of Positron stated, “The introduction of CFR, as a routine non-invasive measurement used in conjunction with cardiac PET imaging, provides a clear differentiator when compared to competing technologies; justifying the expansion of patient indication selection and approval for reimbursement. We believe cfrQuant™ will revolutionize the methodology of diagnosis and subsequent treatment of coronary disease, resulting in improved patient outcomes and cost savings within our heath care system. We look forward to the quick dissemination of this software due to the benefits and advantages it will provide.”

K. Lance Gould, M.D. stated, “The capacity of non-invasive PET for quantitative myocardial perfusion using cfrQuant™ parallels the use of invasive, pressure-based Fractional Flow Reserve (FFR) for assessing physiologic stenosis severity as a guide to management and revascularization procedures. Sophisticated cardiac PET uniquely quantifies diffuse Coronary Artery Disease (CAD) and/or the combination of diffuse and segmental disease that is not routinely feasible with other technologies.”

About Positron: Positron Corporation is a leading molecular imaging healthcare company vertically integrating all the segments of nuclear cardiology—providing an end-to-end solution for cardiac PET. Through proprietary PET imaging systems, radiopharmaceuticals and radioisotopes solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron’s unique products, market position and approach in securing the supply chain are substantial advantages, further accelerating the adoption of cardiac PET and growth of nuclear cardiology. Positron is redefining the industry. More information about Positron is available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as “Risk Factors” in our filings with the Securities and Exchange Commission.

SOURCE Positron Corporation